143 related articles for article (PubMed ID: 2547146)
1. Gangliosides in SV-40-transformed cells derived from Tay-Sachs disease fetal brain.
Hoffman LM; Brooks SE; Stein MR; Adachi M; Schneck L
Metab Brain Dis; 1989 Jun; 4(2):87-93. PubMed ID: 2547146
[TBL] [Abstract][Full Text] [Related]
2. Tay-Sachs disease brain cells in culture: mobilization of stored GM2 after concanavalin A-mediated uptake of hexosaminidase A.
Hoffman LM; Brooks SE; Amsterdam D; Oropello J; Schneck L
J Neurosci Res; 1980; 5(5):413-7. PubMed ID: 7441795
[TBL] [Abstract][Full Text] [Related]
3. Gangliosides containing glucosamine and galactosamine in transformed Tay-Sachs disease and normal human brain cell lines.
Schneck L; Hoffman LM; Brooks SE; Amsterdam D
J Neurol Sci; 1980 Feb; 45(1):123-8. PubMed ID: 6244370
[TBL] [Abstract][Full Text] [Related]
4. Cytology, growth characteristics and cellular alterations following SV40-induced transformation of human foetal brain cells derived from a Gm2 gangliosidosis and control.
Brooks SE; Amsterdam D; Hoffman LM; Adachi M; Schneck L
J Cell Sci; 1979 Aug; 38():211-23. PubMed ID: 230195
[TBL] [Abstract][Full Text] [Related]
5. Ganglioside loading of cultured fibroblasts: a provocative method for the diagnosis of the GM2 gangliosidoses.
Charrow J; Binns HJ
Clin Chim Acta; 1986 Apr; 156(1):41-9. PubMed ID: 2938852
[TBL] [Abstract][Full Text] [Related]
6. GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
Demir SA; Timur ZK; Ateş N; Martínez LA; Seyrantepe V
J Neuroinflammation; 2020 Sep; 17(1):277. PubMed ID: 32951593
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of Tay-Sachs disease using [3H]N-acetylneuraminic acid labelled GM2 ganglioside as substrate.
Poulos A; Holding J; Carey WF
Clin Chim Acta; 1982 Apr; 120(3):331-40. PubMed ID: 6210469
[TBL] [Abstract][Full Text] [Related]
8. Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.
Chen Y; Jian J; Hettinghouse A; Zhao X; Setchell KDR; Sun Y; Liu CJ
J Mol Med (Berl); 2018 Dec; 96(12):1359-1373. PubMed ID: 30341570
[TBL] [Abstract][Full Text] [Related]
9. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
Harzer K
Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
[No Abstract] [Full Text] [Related]
10. Composition of gangliosides and neutral glycosphingolipids of brain in classical Tay-Sachs and Sandhoff disease: more lyso-GM2 in Sandhoff disease?
Rosengren B; Månsson JE; Svennerholm L
J Neurochem; 1987 Sep; 49(3):834-40. PubMed ID: 3612128
[TBL] [Abstract][Full Text] [Related]
11. GM2 ganglioside in fetal Tay-Sachs disease brain cultures: a model system for the disease.
Hoffman LM; Amsterdam D; Schneck L
Brain Res; 1976 Jul; 111(1):109-17. PubMed ID: 953690
[TBL] [Abstract][Full Text] [Related]
12. Effect of modification of sialic acid on enzymic hydrolysis of gangliosides GM1 and GM2.
Li SC; Serizawa S; Li YT; Nakamura K; Handa S
J Biol Chem; 1984 May; 259(9):5409-10. PubMed ID: 6232275
[TBL] [Abstract][Full Text] [Related]
13. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement treatment for Tay-Sachs disease brain cells in culture utilizing concanavalin A-mediated hexosaminidase A uptake: biochemical and morphological evidence of GM2 mobilization.
Brooks SE; Hoffman LM; Adachi M; Amsterdam D; Schneck L
Acta Neuropathol; 1980; 50(1):9-17. PubMed ID: 7376831
[TBL] [Abstract][Full Text] [Related]
15. The protein activator specific for the enzymic hydrolysis of GM2 ganglioside in normal human brain and brains of three types of GM2 gangliosidosis.
Hirabayashi Y; Li YT; Li SC
J Neurochem; 1983 Jan; 40(1):168-75. PubMed ID: 6848657
[TBL] [Abstract][Full Text] [Related]
16. The mutation mechanism causing juvenile-onset Tay-Sachs disease among Lebanese.
Hechtman P; Boulay B; Bayleran J; Andermann E
Clin Genet; 1989 May; 35(5):364-75. PubMed ID: 2527097
[TBL] [Abstract][Full Text] [Related]
17. Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model.
Martino S; Cavalieri C; Emiliani C; Dolcetta D; Cusella De Angelis MG; Chigorno V; Severini GM; Sandhoff K; Bordignon C; Sonnino S; Orlacchio A
Neurochem Res; 2002 Aug; 27(7-8):793-800. PubMed ID: 12374215
[TBL] [Abstract][Full Text] [Related]
18. The metabolism of Tay-Sachs ganglioside: catabolic studies with lysosomal enzymes from normal and Tay-Sachs brain tissue.
Tallman JF; Johnson WG; Brady RO
J Clin Invest; 1972 Sep; 51(9):2339-45. PubMed ID: 4639018
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical demonstration of GM2-ganglioside in the central nervous system of a 19-week-old fetus of Tay-Sachs disease.
Taniike M; Inui K; Hirabayashi Y; Tsukamoto H; Nishimoto J; Midorikawa M; Okada S; Yabuuchi H
J Inherit Metab Dis; 1989; 12 Suppl 2():372-4. PubMed ID: 2512447
[No Abstract] [Full Text] [Related]
20. Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain.
Neuenhofer S; Conzelmann E; Schwarzmann G; Egge H; Sandhoff K
Biol Chem Hoppe Seyler; 1986 Mar; 367(3):241-4. PubMed ID: 3707714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
